Statement on Boosting with the Johnson & Johnson COVID-19 Vaccine


CliniExpert
74
0

Ad26.COV2-S (SARS-CoV-2 vaccine)

 

NEW BRUNSWICK, N.J., August 18, 2021 -- We are engaging with the U.S. FDA, CDC and other health authorities and will share new data shortly regarding boosting with the Johnson & Johnson COVID-19 vaccine.

In July, Johnson & Johnson shared data demonstrating that our single-shot COVID-19 vaccine generated strong, persistent immune activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants. Interim results from a Phase 1/2a study published in the New England Journal of Medicine also showed that the durability of the immune response was strong, with no waning for at least eight months, the length of time that had been evaluated to date.

Ensuring long-term and durable protection against hospitalization and death are critical in curbing the COVID-19 pandemic.

Source: Johnson & Johnson

Posted: August 2021

Hot Info